Products
Solnerstotug Biosimilar Monoclonal Antibody (VISTA) for Research
Cat No.: GMP-Bios-INN-1391
Anti-VSIR/VISTA/B7H5/PD1H/SISP1 therapeutic antibody (Pre-made Solnerstotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Solnerstotug (development code SNS-101) is a humanized monoclonal antibody targeting VISTA (VSIR). It is developed by Sensei Biotherapeutics for Solid tumours in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1391-1mg | 1mg | 3090 |
| GMP-Bios-INN-1391-10mg | 10mg | |
| GMP-Bios-INN-1391-100mg | 100mg | |
| GMP-Bios-INN-1391-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Solnerstotug biosimilar, Whole mAb, Anti-VSIR/VISTA/B7H5/PD1H/SISP1 Antibody: Anti-VISTA/VSIR/V-type immunoglobulin domain-containing suppressor of T-cell activation/Platelet receptor Gi24 therapeutic antibody |
| INN Name | Solnerstotug |
| Target | VSIR/VISTA/B7H5/PD1H/SISP1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 8tbq:HL:AB |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Sensei Biotherapeutics |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
